Akebia Drug Patent Portfolio
Akebia owns 1 orange book drug protected by 13 US patents Given below is the list of Akebia's drug patents along with their expiration dates.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US11324734 | Compositions and methods for treating anemia | 31 Mar, 2036 | Active |
| US11844756 | Compositions and methods for treating anemia | 31 Mar, 2036 | Active |
| US10149842 | Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid, compositions, and uses thereof | 14 Nov, 2034 | Active |
| US11065237 | Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid, compositions, and uses thereof | 14 Nov, 2034 | Active |
| US9701636 | Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid, compositions, and uses thereof | 14 Nov, 2034 | Active |
| US9987262 | Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid, compositions, and uses thereof | 14 Nov, 2034 | Active |
| US11857543 | Compositions and methods for treating anemia | 09 Jun, 2034 | Active |
| US8323671 | Prolyl hydroxylase inhibitors and methods of use | 03 Apr, 2028 | Active |
| US7811595 | Prolyl hydroxylase inhibitors and methods of use | 13 Mar, 2028 | Active |
| US8343952 | Prolyl hydroxylase inhibitors and methods of use | 14 Aug, 2027 | Active |
| US8598210 | Prolyl hydroxylase inhibitors and methods of use | 26 Jun, 2027 | Active |
| US8940773 | Prolyl hydroxylase inhibitors and methods of use | 26 Jun, 2027 | Active |
| USRE47437 | Prolyl hydroxylase inhibitors and methods of use | 26 Jun, 2027 | Active |
Latest Legal Activities on Akebia's Drug Patents
Given below is the list of recent legal activities going on the following drug patents of Akebia.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Information Disclosure Statement (IDS) Filed | 16 Jun, 2025 | US8940773 |
| transaction for FDA Determination of Regulatory Review Period | 16 Jun, 2025 | US8940773 |
| transaction for FDA Determination of Regulatory Review Period | 16 Jun, 2025 | US8343952 (Litigated) |
| Information Disclosure Statement (IDS) Filed | 16 Jun, 2025 | US8343952 (Litigated) |
| transaction for FDA Determination of Regulatory Review Period | 16 Jun, 2025 | US7811595 (Litigated) |
| Information Disclosure Statement (IDS) Filed | 16 Jun, 2025 | US8323671 (Litigated) |
| transaction for FDA Determination of Regulatory Review Period | 16 Jun, 2025 | US8323671 (Litigated) |
| transaction for FDA Determination of Regulatory Review Period | 16 Jun, 2025 | US8598210 (Litigated) |
| Payment of Maintenance Fee, 12th Yr, Small Entity | 21 May, 2025 | US8598210 (Litigated) |
| Mail Patent eCofC Notification | 06 May, 2025 | US8323671 (Litigated) |
| Mail Patent eCofC Notification | 06 May, 2025 | US7811595 (Litigated) |
| Patent eCofC Notification | 06 May, 2025 | US8323671 (Litigated) |
| Email Notification | 06 May, 2025 | US8323671 (Litigated) |
| Patent eCofC Notification | 06 May, 2025 | US8598210 (Litigated) |
| Recordation of Patent eCertificate of Correction | 06 May, 2025 | US7811595 (Litigated) |
Akebia's Family Patents
Akebia Drug List
Given below is the complete list of Akebia's drugs and the patents protecting them.
1. Vafseo
Vafseo is protected by 13 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US11324734 | Compositions and methods for treating anemia |
31 Mar, 2036
(10 years from now)
| Active |
| US11844756 | Compositions and methods for treating anemia |
31 Mar, 2036
(10 years from now)
| Active |
| US10149842 | Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid, compositions, and uses thereof |
14 Nov, 2034
(8 years from now)
| Active |
| US11065237 | Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid, compositions, and uses thereof |
14 Nov, 2034
(8 years from now)
| Active |
| US9701636 | Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid, compositions, and uses thereof |
14 Nov, 2034
(8 years from now)
| Active |
| US9987262 | Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid, compositions, and uses thereof |
14 Nov, 2034
(8 years from now)
| Active |
| US11857543 | Compositions and methods for treating anemia |
09 Jun, 2034
(8 years from now)
| Active |
| US8323671 | Prolyl hydroxylase inhibitors and methods of use |
03 Apr, 2028
(2 years from now)
| Active |
| US7811595 | Prolyl hydroxylase inhibitors and methods of use |
13 Mar, 2028
(1 year, 11 months from now)
| Active |
| US8343952 | Prolyl hydroxylase inhibitors and methods of use |
14 Aug, 2027
(1 year, 4 months from now)
| Active |
| US8598210 | Prolyl hydroxylase inhibitors and methods of use |
26 Jun, 2027
(1 year, 3 months from now)
| Active |
| US8940773 | Prolyl hydroxylase inhibitors and methods of use |
26 Jun, 2027
(1 year, 3 months from now)
| Active |
| USRE47437 | Prolyl hydroxylase inhibitors and methods of use |
26 Jun, 2027
(1 year, 3 months from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Vafseo's drug page
Explore Our Curated Drug Screens
Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List